Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
anti-VEGF agents
|
| gptkbp:alternativeName |
gptkb:E10030
|
| gptkbp:clinicalTrialPhase |
Phase 3 (as of 2016)
|
| gptkbp:combinationTherapy |
gptkb:ranibizumab
|
| gptkbp:developedBy |
gptkb:Ophthotech
|
| gptkbp:failedToMeetEndpoints |
Phase 3 clinical trials
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fovista
|
| gptkbp:indication |
neovascular AMD
|
| gptkbp:intendedUse |
treatment of wet age-related macular degeneration
|
| gptkbp:mechanismOfAction |
anti-PDGF (platelet-derived growth factor) agent
|
| gptkbp:routeOfAdministration |
intravitreal injection
|
| gptkbp:status |
development discontinued
|
| gptkbp:target |
gptkb:PDGF-B
|
| gptkbp:bfsParent |
gptkb:Ophthotech_Corporation
gptkb:Ophthotech |
| gptkbp:bfsLayer |
7
|